Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Eckstein

Showing results (201-210 of 238) with videos related to

Pageof 24
Sort By:
Journal for Immunotherapy of Cancer|October 7, 2020
Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8Markus Hecht, Antoniu Oreste Gostian, Markus Eckstein, et al.
Journal for Immunotherapy of Cancer|August 27, 2021
<i>CTLA4</i> promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinomaNiklas Klümper, Damian J Ralser, Romina Zarbl, et al.
Cell Death & Disease|July 31, 2024
Neutrophil extracellular traps characterize caseating granulomasLeticija Zlatar, Jasmin Knopf, Jeeshan Singh, et al.
European Urology Oncology|July 14, 2026
FGFR3 Testing in Urothelial Carcinoma: An Expert Commentary on Best Practices From Patient Identification to Result ReportingEva M Compérat, Arndt Hartmann, Yves Allory, et al.
British Journal of Cancer|July 21, 2022
pT3 colorectal cancer revisited: a multicentric study on the histological depth of invasion in more than 1000 pT3 carcinomas-proposal for a new pT3a/pT3b subclassificationSebastian Foersch, Corinna Lang-Schwarz, Markus Eckstein, et al.
Annals of the Rheumatic Diseases|August 17, 2024
CD19-CAR T-cell therapy induces deep tissue depletion of B cellsCarlo Tur, Markus Eckstein, Joachim Velden, et al.
Histopathology|March 9, 2025
Interobserver reproducibility of a hybrid three-tier grading system of papillary nonmuscle invasive urothelial carcinoma: an international Uropathology studyMichelle R Downes, Katherine Lajkosz, Ferran Algaba, et al.
Annals of the Rheumatic Diseases|January 28, 2025
CD19-CAR T-cell therapy induces deep tissue depletion of B cellsCarlo Tur, Markus Eckstein, Joachim Velden, et al.
EJNMMI Research|March 17, 2025
Liver-FDG-uptake augments early PET/CT prognostic value for CD19-targeted CAR-T cell therapy in diffuse large B cell lymphomaMichael Beck, Viktoria Blumenberg, Veit L Bücklein, et al.
European Urology Focus|December 18, 2025
Harnessing Artificial Intelligence for Risk Stratification and Outcome Prediction in Urologic Cancers: A Systematic ReviewNavid Roessler, Marcin Miszczyk, Keiichiro Miyajima, et al.
Pageof 24

Showing results (201-210 of 238) with videos related to

Sort By:
Pageof 24
Journal for Immunotherapy of Cancer|October 7, 2020
Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8Markus Hecht, Antoniu Oreste Gostian, Markus Eckstein, et al.
Journal for Immunotherapy of Cancer|August 27, 2021
<i>CTLA4</i> promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinomaNiklas Klümper, Damian J Ralser, Romina Zarbl, et al.
Cell Death & Disease|July 31, 2024
Neutrophil extracellular traps characterize caseating granulomasLeticija Zlatar, Jasmin Knopf, Jeeshan Singh, et al.
European Urology Oncology|July 14, 2026
FGFR3 Testing in Urothelial Carcinoma: An Expert Commentary on Best Practices From Patient Identification to Result ReportingEva M Compérat, Arndt Hartmann, Yves Allory, et al.
British Journal of Cancer|July 21, 2022
pT3 colorectal cancer revisited: a multicentric study on the histological depth of invasion in more than 1000 pT3 carcinomas-proposal for a new pT3a/pT3b subclassificationSebastian Foersch, Corinna Lang-Schwarz, Markus Eckstein, et al.
Annals of the Rheumatic Diseases|August 17, 2024
CD19-CAR T-cell therapy induces deep tissue depletion of B cellsCarlo Tur, Markus Eckstein, Joachim Velden, et al.
Histopathology|March 9, 2025
Interobserver reproducibility of a hybrid three-tier grading system of papillary nonmuscle invasive urothelial carcinoma: an international Uropathology studyMichelle R Downes, Katherine Lajkosz, Ferran Algaba, et al.
Annals of the Rheumatic Diseases|January 28, 2025
CD19-CAR T-cell therapy induces deep tissue depletion of B cellsCarlo Tur, Markus Eckstein, Joachim Velden, et al.
EJNMMI Research|March 17, 2025
Liver-FDG-uptake augments early PET/CT prognostic value for CD19-targeted CAR-T cell therapy in diffuse large B cell lymphomaMichael Beck, Viktoria Blumenberg, Veit L Bücklein, et al.
European Urology Focus|December 18, 2025
Harnessing Artificial Intelligence for Risk Stratification and Outcome Prediction in Urologic Cancers: A Systematic ReviewNavid Roessler, Marcin Miszczyk, Keiichiro Miyajima, et al.
Pageof 24